Winston A - Search Results

1

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

Writing Group; Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. Writing Group, et al. Among authors: winston a. HIV Med. 2014 Jan;15 Suppl 1:1-85. doi: 10.1111/hiv.12119. HIV Med. 2014. PMID: 24330011 Free article. No abstract available.

2

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A. Winston A, et al. AIDS. 2002 Oct 18;16(15):2087-9. doi: 10.1097/00002030-200210180-00018. AIDS. 2002. PMID: 12370512

3

Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy.

Fox P, Stebbing J, Portsmouth S, Winston A, Frances N, Nelson M, Gazzard B, Bower M. Fox P, et al. Among authors: winston a. AIDS. 2003 Jan 24;17(2):279-80. doi: 10.1097/00002030-200301240-00028. AIDS. 2003. PMID: 12545098 No abstract available.

4

Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.

Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, Nelson M. Winston A, et al. AIDS. 2004 Apr 9;18(6):949-51. doi: 10.1097/00002030-200404090-00014. AIDS. 2004. PMID: 15060444 No abstract available.

5

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

Winston A, Pozniak A, Smith N, Fletcher C, Mandalia S, Parmar D, Gibbons S, Back D, Gazzard B, Nelson M. Winston A, et al. AIDS. 2004 Feb 20;18(3):572-4. doi: 10.1097/00002030-200402200-00029. AIDS. 2004. PMID: 15090815 Clinical Trial.

6

Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.

Winston A, Patel N, Back D, Khoo S, Bulbeck S, Mandalia S, Pozniak AL, Nelson M, Moyle G, Gazzard B, Boffito M. Winston A, et al. J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):675-6. doi: 10.1097/01.qui.0000209910.27997.d9. J Acquir Immune Defic Syndr. 2006. PMID: 16652044 No abstract available.

7

The clinical implications of antiretroviral pharmacogenomics.

Fox J, Boffito M, Winston A. Fox J, et al. Among authors: winston a. Pharmacogenomics. 2006 Jun;7(4):587-96. doi: 10.2217/14622416.7.4.587. Pharmacogenomics. 2006. PMID: 16753006 Review.

8

The rationale and development of new drugs to treat HIV infection.

Stebbing J, Hatzimichael E, Bower M, Winston A. Stebbing J, et al. Among authors: winston a. Med Chem. 2005 Nov;1(6):635-42. doi: 10.2174/157340605774598199. Med Chem. 2005. PMID: 16787347 Review.

9

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.

Winston A, Back D, Fletcher C, Robinson L, Unsworth J, Tolowinska I, Schutz M, Pozniak AL, Gazzard B, Boffito M. Winston A, et al. AIDS. 2006 Jun 26;20(10):1401-6. doi: 10.1097/01.aids.0000233573.41597.8a. AIDS. 2006. PMID: 16791014

10

The clinical pharmacology of antiretrovirals in development.

Winston A, Mallon PW, Boffito M. Winston A, et al. Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):447-58. doi: 10.1517/17425255.2.3.447. Expert Opin Drug Metab Toxicol. 2006. PMID: 16863445 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

493 results

Search Page

Filters